These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33008930)

  • 1. Prognostic Value of 16α-
    Yamada S; Tsuyoshi H; Yamamoto M; Tsujikawa T; Kiyono Y; Okazawa H; Yoshida Y
    J Nucl Med; 2021 May; 62(5):636-642. PubMed ID: 33008930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional images reflect aggressiveness of endometrial carcinoma: estrogen receptor expression combined with 18F-FDG PET.
    Tsujikawa T; Yoshida Y; Kudo T; Kiyono Y; Kurokawa T; Kobayashi M; Tsuchida T; Fujibayashi Y; Kotsuji F; Okazawa H
    J Nucl Med; 2009 Oct; 50(10):1598-604. PubMed ID: 19759112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET.
    Tsujikawa T; Yoshida Y; Kiyono Y; Kurokawa T; Kudo T; Fujibayashi Y; Kotsuji F; Okazawa H
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):37-45. PubMed ID: 20717823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of lymph node-to-primary tumor standardized uptake value ratio in endometrioid endometrial carcinoma.
    Chung HH; Cheon GJ; Kim JW; Park NH; Song YS
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):47-55. PubMed ID: 28828510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
    Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
    J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
    Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Tumor Volume on 18F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients.
    Husby JA; Reitan BC; Biermann M; Trovik J; Bjørge L; Magnussen IJ; Salvesen ØO; Salvesen HB; Haldorsen IS
    J Nucl Med; 2015 Aug; 56(8):1191-8. PubMed ID: 26045311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta-estradiol and 18F fluorodeoxyglucose PET--initial experience.
    Tsujikawa T; Yoshida Y; Mori T; Kurokawa T; Fujibayashi Y; Kotsuji F; Okazawa H
    Radiology; 2008 Aug; 248(2):599-605. PubMed ID: 18539894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG/18F-FES standardized uptake value ratio determined using PET predicts prognosis in uterine sarcoma.
    Yamamoto M; Tsujikawa T; Yamada S; Kurokawa T; Shinagawa A; Chino Y; Mori T; Kiyono Y; Okazawa H; Yoshida Y
    Oncotarget; 2017 Apr; 8(14):22581-22589. PubMed ID: 28186981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
    Zhao Z; Yoshida Y; Kurokawa T; Kiyono Y; Mori T; Okazawa H
    J Nucl Med; 2013 Apr; 54(4):499-506. PubMed ID: 23471314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F]fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer.
    Liu C; Xu X; Yuan H; Zhang Y; Zhang Y; Song S; Yang Z
    Front Oncol; 2020; 10():580277. PubMed ID: 33251143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic tumour volume and total lesion glycolysis, measured using preoperative 18F-FDG PET/CT, predict the recurrence of endometrial cancer.
    Shim SH; Kim DY; Lee DY; Lee SW; Park JY; Lee JJ; Kim JH; Kim YM; Kim YT; Nam JH
    BJOG; 2014 Aug; 121(9):1097-106; discussion 1106. PubMed ID: 24397772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.
    van Kruchten M; de Vries EF; Arts HJ; Jager NM; Bongaerts AH; Glaudemans AW; Hollema H; de Vries EG; Hospers GA; Reyners AK
    J Nucl Med; 2015 Jan; 56(1):50-5. PubMed ID: 25476534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in lymph node metastases and risk stratification of endometrial carcinoma.
    Liu DD; Li J; Li X; Xie L; Qin L; Peng F; Cheng MH
    J Gynecol Oncol; 2019 Nov; 30(6):e89. PubMed ID: 31576685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer.
    Kidd EA; Siegel BA; Dehdashti F; Grigsby PW
    Cancer; 2010 Mar; 116(6):1469-75. PubMed ID: 20108309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
    Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
    Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid PET/MRI in Staging Endometrial Cancer: Diagnostic and Predictive Value in a Prospective Cohort.
    Ironi G; Mapelli P; Bergamini A; Fallanca F; Candotti G; Gnasso C; Taccagni GL; Sant'Angelo M; Scifo P; Bezzi C; Bettinardi V; Rancoita PMV; Mangili G; Bocciolone L; Candiani M; Gianolli L; De Cobelli F; Picchio M
    Clin Nucl Med; 2022 Mar; 47(3):e221-e229. PubMed ID: 35067539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of preoperative metabolic tumor volume measured by ¹⁸F-FDG PET/CT and MRI in patients with endometrial cancer.
    Chung HH; Lee I; Kim HS; Kim JW; Park NH; Song YS; Cheon GJ
    Gynecol Oncol; 2013 Sep; 130(3):446-51. PubMed ID: 23791826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
    Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.